| NCT00139841 | Non-Hodgkin's Lymphoma | Drug: Bendamustine HCl | Cephalon|Teva Pharmaceutical Industries | Phase 3 | 2005-10-01 | 2014-05-08 |
| NCT00705250 | Hodgkin's Disease|Lymphoma | Drug: bendamustine hcl | Memorial Sloan Kettering Cancer Center|Cephalon | Phase 2 | 2008-06-01 | 2017-01-18 |
| NCT00867503 | Ovarian Cancer | Drug: Bendamustine HCL | University of Arizona|Cephalon | Phase 2 | 2009-02-01 | 2015-12-02 |
| NCT00959686 | T-cell Lymphoma | Drug: Bendamustine | French Innovative Leukemia Organisation|Mundipharma Pte Ltd. | Phase 2 | 2009-09-01 | 2013-02-11 |
| NCT01500083 | Indolent Non-Hodgkin's Lymphoma|Chronic Lymphocytic Leukemia | Drug: Bendamustine at a dose of 100 mg/m2|Drug: Bendamustine at a dose of 120 mg/m2 | Lundbeck Canada Inc. | Phase 3 | 2012-03-01 | 2014-10-16 |
| NCT01626352 | Diffuse Large B-Cell Lymphoma | Drug: Bendamustine|Drug: Ofatumumab | SCRI Development Innovations, LLC|Novartis|GlaxoSmithKline|Cephalon | Phase 2 | 2012-08-01 | 2017-02-14 |
| NCT00076349 | Non-Hodgkin's Lymphoma | Drug: bendamustine and rituximab | Cephalon|Teva Pharmaceutical Industries | Phase 2 | 2004-04-01 | 2014-05-08 |
| NCT00947388 | Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Stage III Chronic Lymphocytic Leukemia|Stage III Small Lymphocytic Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Small Lymphocytic Lymphoma | Drug: Bendamustine Hydrochloride|Biological: Alemtuzumab | Case Comprehensive Cancer Center|Cephalon | Phase 1 | 2008-11-01 | 2013-08-20 |
| NCT01010568 | Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma | Drug: Ofatumumab and Bendamustine | Georgetown University|GlaxoSmithKline|Cephalon | Phase 2 | 2010-04-01 | 2015-11-10 |
| NCT01596621 | Non-Hodgkin Lymphoma | Drug: Bendamustine hydrochloride | Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries | Phase 3 | 2012-07-01 | 2016-12-01 |
| NCT01929265 | Indolent Non-follicular|Non-Hodgkin's Lymphoma | Drug: Bendamustine | Fondazione Italiana Linfomi ONLUS | Phase 2 | 2011-01-01 | 2017-03-22 |
| NCT01022021 | Lymphoma | Drug: Rituximab|Drug: Bendamustine | University of Kansas Medical Center|Cephalon | Early Phase 1 | 2010-01-01 | 2017-01-06 |
| NCT01152203 | Advanced Cancer | Drug: Bendamustine|Drug: Bevacizumab | M.D. Anderson Cancer Center|Cephalon|National Comprehensive Cancer Network | Phase 1 | 2010-06-01 | 2015-11-16 |
| NCT02315157 | Multiple Myeloma|Plasma Cell Leukemia | Drug: Bendamustine | Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University | Phase 1 | null | 2016-10-19 |
| NCT01077518 | Lymphoma, Follicular | Drug: Ofatumumab and Bendamustine infusions (Arm A)|Drug: Bendamustine infusion (Arm B) | Novartis Pharmaceuticals|Novartis | Phase 3 | 2010-08-01 | 2016-08-07 |
| NCT00426855 | Lymphoma, Non-Hodgkin | Drug: Bendamustine|Drug: Bortezomib | Peter Moosmann|Kantonsspital Aarau | Phase 1|Phase 2 | 2007-01-01 | 2015-04-02 |
| NCT01296256 | Bendamustine|Conditioning Therapy|Autologous Stem Cell Transplant|Aggressive Non Hodgkin's Lymphoma | Drug: Bendamustine-EAM | Grupo Espa帽ol de Linfomas y Transplante Aut贸logo de M茅dula 脫sea | Phase 2 | 2011-05-01 | 2016-02-15 |
| NCT00831597 | Diffuse Large B-Cell Lymphoma | Drug: bendamustine|Drug: rituximab | Pharmatech|Cephalon | Phase 2 | 2008-11-01 | 2016-04-18 |
| NCT01315873 | Multiple Myeloma | Drug: Bendamustine|Drug: Bortezomib | New York University School of Medicine|Cephalon | Phase 2 | 2011-09-01 | 2016-09-08 |
| NCT01657331 | Hodgkin Lymphoma|Anaplastic Large Cell Lymphoma | Drug: Brentuximab Vedotin|Drug: Bendamustine|Drug: Neulasta | Owen A. O'Connor|British Columbia Cancer Agency|Princess Margaret Hospital, Canada|Columbia University | Phase 1|Phase 2 | 2012-07-01 | 2017-02-01 |
